ReviewJournal of clinical and translational hepatology2021
Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease.
Review in Journal of clinical and translational hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Post COVID Condition and Long-Term COVID-19 Impact on Hepatic Decompensation and Survival in Cirrhosis: A Propensity Matched Observational Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Therapeutic effects of mesenchymal stromal cell secretome in liver fibrosis with acute lung injury.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Synergistic Protection of Vitamin B Complex and Alpha-Lipoic Acid Against Hepatic Ischemia-Reperfusion Injury: Boosting Antioxidant Defenses in Rats.Current issues in molecular biology · 2024Article
- Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.Journal of clinical and translational hepatology · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Clinical characteristics and the role of IL-6 in acute-on-chronic liver failure patients with or without COVID-19: a multicenter paired cohort study.Frontiers in cellular and infection microbiology · 2024Article
- Cirrhosis with COVID-19: Just another infection or something more to it?JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies.World journal of gastroenterology · 2023Review
- Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.World journal of gastroenterology · 2023Review
- An Interplay between Oxidative Stress (Lactate Dehydrogenase) and Inflammation (Anisocytosis) Mediates COVID-19 Severity Defined by Routine Clinical Markers.Antioxidants (Basel, Switzerland) · 2023Article
- Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.Frontiers in cellular and infection microbiology · 2023Observational
- Age-dependent immune responses in COVID-19-mediated liver injury: focus on cytokines.Frontiers in endocrinology · 2023Review
- Review
- In silico prediction of COVID-19 cytokine storm in lung cancer types.Biochemistry and biophysics reports · 2022Article
- Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases.World journal of gastroenterology · 2022Review
- Early Biochemical Markers in Predicting the Clinical Outcome of COVID-19 Patients Admitted in Tertiary Care Hospital.Journal of laboratory physicians · 2022Article
- Work-up for Incidentally Detected NAFLD: How Far is It Worth?Euroasian journal of hepato-gastroenterology · 2022Review
- Patterns of liver profile disturbance in patients with COVID-19.World journal of clinical cases · 2022Review
- The des-ArgFrontiers in physiology · 2022Article
- Tobacco, Cigarettes, and the Liver: The Smoking Gun.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus pandemic has resulted in increased rates of hepatic decompensation, morbidity and mortality in patients suffering from existing liver disease, and deranged liver biochemistries in those without liver disease. In patients with cirrhosis with coronavirus disease 2019 (COVID-19), new onset organ failures manifesting as acute-on-chronic liver failure have also been reported. The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) also directly binds to enterocytes and cholangiocytes via the angiotensin converting enzyme receptor 2, although the lung remains the portal of entry. Superadded with the COVID-19 related bystander hepatitis, a systemic inflammatory response is noted due to unregulated macrophage activation syndrome and cytokine storm. However, the exact definition and diagnostic criteria of the 'cytokine storm' in COVID-19 are yet unclear. In addition, inflammatory markers like C-reactive protein, ferritin, D-dimer and procalcitonin are frequently elevated. This in turn leads to disease progression, activation of the coagulation cascade, vascular microthrombi and immune-mediated injury in different organ systems. Deranged liver chemistries are also noted due to the cytokine storm, and synergistic hypoxic or ischemic liver injury, drug-induced liver injury, and use of hepatotoxic antiviral agents all contribute to deranged liver chemistry. Control of an unregulated cytokine storm at an early stage may avert disease morbidity and mortality. Several immunomodulator drugs and repurposed immunosuppressive agents have been used in COVID-19 with varying degrees of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.